Fc-engineered human IgG1 expression vectors featuring DE, DLE, ADE, GASDALIE, and G236A mutations for investigating enhanced Fc receptor interactions, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
Compare five Fc-engineered human IgG1 expression vectors to select an appropriate variant for your antibody engineering research.
| Catalog No. | Variant | Engineering Mechanism | Selection Guidance |
|---|---|---|---|
| AFV-01 | Human IgG1 (DE) | S239D / I332E | Two-residue Fc engineering for enhanced Fcγ receptor engagement. |
| AFV-02 | Human IgG1 (DLE) | S239D / A330L / I332E | Three-residue Fc engineering for ADCC-focused studies. |
| AFV-17 | Human IgG1 (GASDALIE) | G236A / S239D / A330L / I332E | Four-residue Fc engineering for ADCC/ADCP research and Fcγ receptor interaction studies. |
| AFV-18 | Human IgG1 (ADE) | G236A / S239D / I332E | Combined Fc engineering for ADCC/ADCP studies. |
| AFV-19 | Human IgG1 (G236A) | G236A | Single-residue variant for investigating FcγRIIa-related interactions and phagocytosis. |
Functional enhancement depends on antibody sequence, Fc receptor subtype and polymorphism, target cells, and assay conditions. Confirm Fcγ receptor binding and ADCC/ADCP activity experimentally.
Showing all 5 results